Monday, 20 Jan 2020

You are here

GCA: Uptick in Severe Infections in First Year

Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.

During the first year after GCA was diagnosed, the incidence rate of infections resulting in hospitalization was 11.1 per 100 patient-years versus 5.9 per 100 among controls, according to Jean Schmidt, MD, PhD, of Amiens University Hospital in Amiens, and colleagues.

Accordingly, the incidence rate ratio for severe infection was 2.1 (95% CI 1.2-3.4), the researchers reported online in Arthritis & Rheumatology.

GCA is the most common type of vasculitis. It develops in older patients and affects medium and large-sized arteries. Corticosteroid treatment dramatically suppresses the symptoms of GCA and can prevent the ocular complications, but adverse effects, including life-threatening infections, can occur.

Efforts to identify steroid-sparing treatments have had only limited success. Methotrexate has shown modest benefits, but tumor necrosis factor inhibitors such as infliximab (Remicade) have not been effective.

The study included 486 patients diagnosed with GCA from 1991 to 2009, drawn from 40 centers in France. Almost 75% were women, and mean age was 74. Age- and sex-matched controls were recruited from the representative city of Saint Etienne.

Participants were followed every 6 months for about 5 years. At each visit, clinicians collected information on infections, corticosteroid dose, and other relevant data.

Patients who developed severe infections were older at baseline (77 versus 74 years,P<0.0001).

During the first year after diagnosis, septic shock and colitis were significantly more common among GCA patients (P=0.03). Pneumonia and pyelonephritis also occurred more often, and four GCA patients developed tuberculosis.

"Close clinical monitoring, early antibiotic treatment, and specific screening for tuberculosis before treatment may be ways to reduce severe infections in patients with CGA," the authors wrote.

The researchers also considered whether mortality among GCA patients changed during the years of the study, and found that in the earlier period, before 1997, overall mortality was increased in patients with GCA (HR 2.4, 95% CI 1.5-3.9,P=0.0002). After Jan. 1, 1997, overall mortality was similar among patients and controls.

"This improvement may reflect better care or a change in the severity of the disease in the recruited patients," the authors noted.

In a multivariate model adjusting for age at inclusion and the period of enrollment, the factors associated with overall mortality were a diagnosis of GCA (HR 2.22, 95% CI 1.54-3.21,P<0.0001), severe infection (HR 2.14, 95% CI 1.49-3.06,P<0.0001), and a diagnosis of cancer during follow-up (HR 2.08, 95% CI 1.30-3.33,P=0.0022).

"Surprisingly," gender was not a risk factor for all-cause mortality in this study. "The size and the length of follow-up of our study were probably too limited to show a difference between women and men," Schmidt and colleagues wrote.

Infections were the cause of death in 28% of GCA patients compared to 6.5% of deaths in the general population.

Mortality caused by an infection was especially increased in GCA patients with diabetes, which can be worsened or induced by corticosteroid therapy (HR 3.3, 95% CI 1.4-7.7,P=0.006) and in those requiring more than 10 mg/day of steroids after a year of treatment (HR 4.61, 95% CI 1.38-15.36,P=0.0127).

The influence of corticosteroids on infection risk is complex, the authors explained, and can involve decreased proliferation and migration of lymphocytes, impaired cellular immune responses and neutrophil adhesion, and cytokine inhibition. The use of steroids also could delay diagnosis of infections in this elderly population who may have fewer systemic symptoms such as fever.

"These data underscore the importance of identifying newer treatments for GCA that would reduce or eliminate the use of corticosteroids," said Kenneth J. Warrington, MD, of the Mayo Clinic in Rochester, Minn., who was not involved in the study.

One such approach being investigated is interleukin-6 inhibition with tocilizumab (Actemra).

"The study adds to the growing literature regarding complications that are seen in patients with GCA, and the importance of better and safer treatments," Warrington toldMedPage Today.

Although the study "does alert providers to be vigilant for infections in patients with GCA," it is not likely to have a significant immediate impact on clinical practice, he said. Nonetheless, because the clinical characteristics of the study participants were similar to those of GCA patients elsewhere, the findings "should be generalizable to the U.S. population," he added.

A possible study limitation was that the patients and controls weren't drawn from the same population.

Schmidt and co-authors disclosed no relevant relationships with industry.

This article brought to RheumNow by our friends at MedPage Today. It was originally published on February 3, 2016.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Can the Happiest Subspecialists Experience Burnout?

The Medscape’s Physician Lifestyle & Happiness Report 2019 crowned rheumatologists as the happiest subspecialists. We topped the list with 65% of the respondents indicating that they were happy outside of work. I was not really surprised by reading that, and I would go as far as saying that our field is the best. 

Rise in Fatty Liver Disease Linked to Obesity and Diabetes

Gut has published population results from NHANES population study showing that the prevalence of fatty liver disease is rising in the US and is driven by obesity and diabetes.

Employed Physicians Outnumber Self-Employed

For the first time in the United States, employed physicians outnumber self-employed physicians, according to a newly updated study on physician practice arrangements by the American Medical Association (AMA). This milestone marks the continuation of a long-term trend that has slowly shifted the distribution of physicians away from ownership of private practices.


Dr. Harold E. Paulus (1929-2019)

Dr. Harold “Hal” Paulus lives in the annals of Rheumatology as a major contributor, mentor, researcher and clinical trialist. He passed away last week, one day after his 89th birthday. I met Dr. Paulus as a fellow in 1985, when he easily included me in his discussions and research on rheumatoid arthritis. I admired his easy demeanor, wry humor and every man character. Most remark on his calm recessive and kind personality that was complemented by a body of work that was large, impactful and usually at the cutting edge. Many of Dr. Paulus’ colleagues and friends have contributed their testimonies and fond memories of this great man.

RheumNowLive On Demand: The History of Steroids - Dr. Eric Matteson

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.